Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population
NCT02661490
Completed
The purpose of this study is to further develop a formulation and dose regimen of the norovirus GI.1/GII.4 bivalent virus-like particle (VLP) vaccine that is immunogenic and safe in an elderly population aged 60 years and above.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2020
Locations: Simon Williamson Clinic, Birmingham, Alabama +9 locations
Conditions: Norovirus
Register for Updates
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
NCT01611298
Completed
This research study is for subjects that are receiving a bone marrow transplant. As part of the transplant subjects will receive stem cells from a donor who has agreed to donate stem cells for them. Unfortunately, it takes a long time for the immune system to recover after a bone marrow transplant. This makes it more likely for patients to develop serious infections. This study is being done to better understand how the immune system will recover after transplant. The immune system includes the... Read More
Gender:
ALL
Ages:
Between 3 years and 70 years
Trial Updated:
04/20/2020
Locations: Texas Childen's Hospital, Houston, Texas +1 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Register for Updates
Vaccine Therapy in Treating Patients With Breast Cancer
NCT00524277
Completed
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells that express HER2/neu. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether vaccine therapy is more effective than GM-CSF in treating breast cancer. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with GM-CSF in treating patients with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/23/2020
Locations: Sibley Memorial Hospital, Washington, District of Columbia +12 locations
Conditions: Breast Cancer
Register for Updates
LT Vaccine Patch Self-Administration Study
NCT00565461
Completed
To evaluate the immune responses achieved following self-administered heat-labile enterotoxin of E. coli (LT) vaccination by transcutaneous immunization compared to the immune responses achieved by clinician-administered vaccination.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/17/2020
Locations: Arkansas Medical Research Testing, Little Rock, Arkansas +2 locations
Conditions: Prevention of Travelers' Diarrhea
Register for Updates
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
NCT02019524
Completed
This is a single-center, randomized, single-blinded, three-arm phase Ib study of the folate binding protein vaccines E39 and J65. The study target population are patients with breast or ovarian cancer diagnosis who have been treated and are without evidence of disease. Disease-free subjects after standard of care multi-modality therapy will be screened and HLA typed. E39 and J65 are cytotoxic T-lymphocyte-eliciting peptide vaccines that are restricted to HLA-A2+ patients (approximately 50% of th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/16/2020
Locations: University of Texas M.D. Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer, Ovarian Cancer
Register for Updates
Nivolumab With DC Vaccines for Recurrent Brain Tumors
NCT02529072
Completed
Patients will be randomized to one of two treatment arms - Group I and Group II. Group I will receive nivolumab monotherapy until surgical resection, and Group II will receive nivolumab alone and with DC vaccine therapy until surgical resection. During surgical resection blood and tumor samples will be assessed and compared. Following surgery, both groups will continue to receive DC vaccines (total of 8) and nivolumab therapy until confirmed progression.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/11/2020
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Malignant Glioma, Astrocytoma, Glioblastoma
Register for Updates
Cholecalciferol and Flu Vaccine in Treating Healthy Participants
NCT01561989
Terminated
This randomized clinical trial studies cholecalciferol and flu vaccine in treating healthy participants. Cholecalciferol may increase the immunologic response of flu vaccine in healthy participants. Flu vaccine may help the body build an immune response and help prevent flu
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/02/2020
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Healthy, no Evidence of Disease
Register for Updates
Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response
NCT03701061
Completed
The study is a prospective single site exploratory study to examine the impact of Food and Drug Administration (FDA) approved seasonal flu vaccine on the immune responses of H5N1 vaccine previously received with or without the AS03 adjuvant.
Gender:
ALL
Ages:
All
Trial Updated:
02/28/2020
Locations: The Hope Clinic of Emory University, Decatur, Georgia
Conditions: Influenza A Subtype H5N1 Infection
Register for Updates
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
NCT00836407
Completed
Research Hypothesis: Ipilimumab (an antibody that blocks negative signals to T cells) administered alone or in combination with a pancreatic cancer vaccine (allogeneic pancreatic tumor cells transfected with a GM-CSF gene), has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma. Primary Objective: To determine the safety profile of ipilimumab alone or in combination with a pancreatic cancer vaccine in subjects with locally advanc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2020
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
NCT01447407
Completed
This partially-blind, placebo controlled study is a Phase 1b study using an investigational vaccine, NDV-3, directed against Staphylococcus aureus and Candida sp. This study will compare NDV-3 administered with or without alum delivered intramuscularly (IM) at one dose level. It will also evaluate a lower dose of NDV-3 without alum delivered intradermally (ID) compared to placebo delivered ID.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
02/20/2020
Locations: Cetero Research Clinical Site, Fargo, North Dakota
Conditions: Staphylococcal Infections, Yeast Infections, Candidiasis
Register for Updates
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
NCT02429583
Terminated
This study will investigate the effects of chronic HCV infection and corresponding innate immune activation on the immune response to HBV vaccination. We will recruit chronic HCV patients and healthy control patients for HBV vaccination. We will use RNA Sequencing (RNA-Seq), a relatively new technology for simultaneously measuring the expression of all genes, to determine patients' innate immune status, and learn how this innate immune signature is related to HBV vaccine response. We will then e... Read More
Gender:
ALL
Ages:
Between 18 years and 62 years
Trial Updated:
02/20/2020
Locations: Rockefeller University Hospital, New York, New York
Conditions: Hepatitis C Infection
Register for Updates
Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects
NCT03264157
Completed
A prospective, randomized, blinded, parallel-group, non-inferiority, phase II/III study of the safety and effectiveness of simulated post-exposure prophylaxis with BPL HRIG with co-administration of active rabies vaccine in healthy subjects.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/12/2020
Locations: Prism Research, Saint Paul, Minnesota +1 locations
Conditions: Healthy
Register for Updates